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pre-speciﬁed efﬁcacy results been disclosed?Phase 2 clinical trials are of vital importance in the drug devel-
opment process as they usually gather preliminary evidence of ef-
ﬁcacy of potentially new therapies and support the go/no-go
decision for Phase 3 pivotal trials. Topline results of Phase 2 trials
are typically ﬁrst disclosed through press releases so that key stake-
holders (patients and their advocacy groups, physicians, clinical tri-
als practitioners, investors, etc.) can have timely access to a high
level summary of the important ﬁndings. The sponsors of the trials
oftenwill savemore detailed ﬁndings for futuremedical conference
presentations and/or peer-reviewed journal publications, and as a
result there may be an extended period of time where only the
topline results are available on which stakeholders can rely. It is
therefore critical for trial sponsors to release objective ﬁndings
and avoid selective disclosure of favorable results.
We have reviewed a large number of press releases for Phase 2
clinical trial results. Given some of the common issues we have
encountered during the review we would like to highlight the
following points for trial sponsors to consider when drafting a press
release:
 If a sponsor decides to report the p-value for the primary
endpoint analysis, the pre-speciﬁed analysis method associated
with that p-value should be disclosed. The American Statistical
Association recently [1] released a statement on p-values, which
includes the deﬁnition of a p-value and some guiding principles
on the reporting and interpretation of p-values. The statement
pointed out that proper interpretation requires full reporting
and transparency. To quote from the statement: “Conducting
multiple analyses of the data and reporting only those with
certain p-values (typically those passing a signiﬁcance
threshold) renders the reported p-values essentially uninter-
pretable”. In addition, it is important to clarify whether one- or
two-sided p-values are reported. Particularly, if a one-sided p-
value is reported, it should be clearly stated in the press release.
 The analysis population should be clearly deﬁned, and if some
enrolled patients have been excluded from the analysis, both the
criteria for the exclusions and whether these criteria were pre-
speciﬁed prior to observing the trial results should be stated.We
have encountered a number of cases where a press release
mentions the total number of patients enrolled in a trial leaving
readers with the impression that the analyses were performed
with data from all the patients, only to later learn in a publica-
tion that a large percentage of patients were excluded from the
analyses for various reasons. Common reasons for exclusions
include 1) patients taking medications during the trial that mayhttp://dx.doi.org/10.1016/j.conctc.2016.11.001
2451-8654/© 2016 Published by Elsevier Inc. This is an open access article under the CCconfound the outcome assessments; 2) patients randomized to
the treatment arm having serum drug concentration levels
below a certain threshold, leaving the sponsor to believe that
there were dosing compliance issues; and 3) patients being
assessed for efﬁcacy not close enough to a speciﬁed study visit
date. There is the potential for bias if some of the reasons are
determined after observing the trial results. For example, for a 6-
month efﬁcacy assessment one patient may be assessed 5 days
earlier and another patient may be assessed 6 days later. If the
analysis requires patients to be assessed within 5 days of a
particular assessment time point, then the latter patient will be
excluded.
 If results for a pre-speciﬁed subgroup are included, more details
on the pre-speciﬁed subgroups should be disclosed. In partic-
ular, the number of subgroups and whether some of the sub-
groups were hypothesized to be more likely to demonstrate a
treatment effect than others would help readers interpret the
totality of the subgroup results.
To further elaborate on the importance of stating the pre-
speciﬁed analysis method, we have seen many cases where the
press releases claim positive trial results with small p-values, and
we learned in subsequent presentations/publications that some
post hoc and uncommon, if not invalid, analysis methods were
used to generate the small p-values. We conducted a simulation
study to illustrate the magnitude of the inﬂation of false positive
rates when selecting the smallest p-value based on multiple anal-
ysis methods. In this study we simulated 10,000 randomized Phase
2 trials comparing an experimental treatment with the standard of
care (SOC) with 50 patients per arm, where the experimental treat-
ment is not superior over the SOC and both treatment arms have a
true response rate of 40%. For each patient we considered three
baseline variables, the ﬁrst variable being binary with equal chance
of taking either outcome (e.g. gender), the second variable being
continuous with a uniform distribution taking values between
0 and 1, and the third variable being continuous with a standard
normal distribution. For each simulated trial we analyzed the trial
results with Fisher's exact test and logistic regression including
one or more of the variables and their interactions with treatment
and calculated the smallest p-value corresponding to these ana-
lyses. Our simulation results show that about 15% of the simulated
trials had the smallest two-sided p-value being less than 0.05, and
about 30% of the simulated trials had the smallest one-sided p-
value being less than 0.05. For those stakeholders who consider a
trial to be positive when the p-value passes the signiﬁcanceBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Z. Su, C. Livoti / Contemporary Clinical Trials Communications 4 (2016) A1eA2A2threshold of 0.05, the false positive rate has been tripled when the
smallest two-sided p-value is presented and even sextupled when
the smallest one-sided p-value is presented without further details.
The false positive rate will be further inﬂated if more analysis ap-
proaches (e.g. stratiﬁed analysis or analyses conducted with some
patients excluded) are considered. This example highlights the
importance of disclosing the pre-speciﬁed analysis approach for a
Phase 2 trial.
The Journal strives to promote the objective disclosure of clinical
trial topline results. We welcome the publication of trial design ar-
ticles that include detailed descriptions of the pre-speciﬁed anal-
ysis approach, and we welcome our readers to bring to our
attention potentially misleading press releases. The global clinical
trials community will beneﬁt from more dedicated effort on thedissemination of objective clinical trials ﬁndings.Reference
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